A phase I/II study of preoperative TS-1 combined chemoradiation therapy for patients with large type 3 or type 4 gastric cancer (OGSG 1303)

Not Applicable

• Conditions: gastric cancer

• Registration Number: JPRN-UMIN000013821
• Lead Sponsor: Osaka Gastrointestinal cancer chemotherapy Study Group (OGSG)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-04-28
• Study Completion: 2021-08-06
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

Not provided

Exclusion Criteria

1) with active double cancers excluding carcinoma in situ and/or prior cancer cured with longer than 5 year interval period 2) with a history of severe allergy against medicine 3) with infectious disease and febrile condition (over 38 centigrade) 4) pregnant or nursing female 5) male expecting pregnancy of partner 6) with a history of cardiac infarction within 6 months 7) under continuous steroids medication 8) Patients who are received systemic continuous administration of flucytosine, phenytoin or warfarin 9) bleeding from gastrointestinal tract 10) with uncontrollable diarrhea (watery stool and/or frequent diarrhea) 11) with HBs antigen+, and/or HCV-antibody+ 12) with severe diseases: autoimmune diseases, intestinal paralysis, interstitial pneumonitis/pulmonary fibrosis, ischemic cardiac diseases 13) Any other patients whom the physician in charge of the study judges to be unsuitable

Study & Design

• Study Type: Interventional
• Study Design: Not specified